Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for men and women diagnosed with ischemic heart disease (myocardial ischemia) who are eligible to be treated with coronary angioplasty (PCI).

This clinical trial is for men and women age 18 and older with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 

Key Inclusion / Exclusion Criteria:
  • Women and men age 18 and older. 
  • Pathologically confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) 
  • Have received at least one prior therapy for CLL/SLL 
  • Detailed eligibility reviewed when you contact the study team. 

This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with Peripheral T-cell Lymphoma (PTCL) who have received no prior systemic therapy.

Key Inclusion / Exclusion Criteria:

   • Women and men age 18 and older with histologically confirmed diagnosis of Peripheral T-cell Lymphoma 
   • No prior systemic therapy for lymphoma 
   • Detailed eligibility reviewed when you contact the study team

Video of A Phase II Study of CC486-CHOP in Previously Untreated Peripheral T-cell Lymphoma

This research study is for pregnant women who have either Crohn’s disease or ulcerative colitis.

Key Inclusion / Exclusion Criteria:
  • Pregnant women with Crohn's disease or ulcerative colitis
  • Age 18 to 50

This clinical trial is for men and women age 18 and older with previously treated CLL/SLL, MCL, FL, MZL, DLBCL, or RTL. Relapsed or refractory hematological cancers are serious, disabling, and life-threatening disorders.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Histologically confirmed diagnosis of CLL/SLL, MCL, FL, MZL, DLBCL, or RTL 
  • Hematological cancer has been previously treated and has progressed during or relapsed after prior systemic therapy. 
  • Detailed eligibility reviewed when you contact the study team. 

    

This clinical trial is a Phase 1 study evaluating the safety of LAM-003 when administered to men and women with previously treated relapsed or refractory AML. Currently, there is a great unmet need for treating AML that has either not responded to or returned after other treatments.

Key Inclusion / Exclusion Criteria:
  • The study is open to men and women aged 18 years or older with a diagnosis of acute myeloid leukemia (AML). 
  • Subjects’ AML must have been previously treated and has progressed during or relapsed after prior therapy. 
  • Detailed eligibility will be reviewed by the study team. 

This clinical trial is for men and women with high-grade gliomas that has recurred for the first time. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women above the age of 18 who have been diagnosed with high-grade gliomas 
  • Histologically confirmed diagnosis of IDH-mutant high-grade (III or IV) glioma 
  • First recurrence of glioma 
  • Detailed eligibility will be reviewed when you contact the study team 

This is a phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, effectiveness of BLU-667 administered orally in patients.

Key Inclusion / Exclusion Criteria:
  • Open to women and men age 18 and older 
  • Diagnosis pathologically documented, definitively diagnosed as non-resectable advanced solid tumor (e.g. thyroid, non small cell lung, colon) 
  • Patient must have non-resectable disease that has progressed following standard therapy or has not adequately responded to standard therapy, or the patient must be intolerant to available standard therapies, or there must be no accepted standard therapy for their disease
  • Detailed eligibility reviewed when you contact the study team

The purpose of this study is to test the safety of the combination of multiple drugs: brentuximab vedotin which is approved for use in relapsed Hodgkin lymphoma, ipilimumab and nivolumab both drugs which stimulate your immune system, and which are approved for use in other cancers, but are

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older. 
  • Patients must have pathologically confirmed relapsed or refractory classical Hodgkin Lymphoma (cHL). 
  • Prior treatment with brentuximab vedotin is OK as long as it has not been within the past 6 months and your cancer did not come back within 6 months of completing this treatment. 
  • Patients may not have received prior nivolumab 
  • Patients should not have other serious, uncontrolled medical conditions 
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.